Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis

Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab su...

Full description

Bibliographic Details
Published in:Türk Oftalmoloji Dergisi
Main Authors: Tülay Şimşek, Nilgün Yıldırım, Belgin Efe, Nur Kebapçı
Format: Article
Language:English
Published: Turkish Ophthalmology Society 2017-01-01
Subjects:
Graves’ orbitopathy
rituximab
psoriasis
Online Access:http://www.oftalmoloji.org/article_14247/Rituximab-Treatment-In-A-Patient-With-Active-Graves-Orbitopathy-And-Psoriasis
Description
Summary:Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves’ orbitopathy. Here we report a case of a 49-year-old woman with Graves’ orbitopathy and psoriasis. The patient received 2 infusions of 1 g rituximab 2 weeks apart. Although there was improvement in inflammatory signs of the disease, proptosis did not change after the treatment.
ISSN:1300-0659
2147-2661

Similar Items